.JPG?ad=18503&adview=true)
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Laboratory of Receptor Biology and Department of Medicine [J. B., Y-M. K., J. M.] and Breast Cancer Medicine Service [J. B., L. N.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021; and Medical Oncology Service, Vall d'Hebron University Hospital, 08035 Barcelona, Spain [J. B., J. A.]
Recombinant humanized anti-HER2 antibody, rhuMAb HER2, inhibits the growth of breast cancer cells overexpressing HER2 and has clinical activity. We explored in preclinical models its capacity to enhance the tumoricidal effects of paclitaxel and doxorubicin. In cultures of naturally HER2-overexpressing cancer cells, rhuMAb HER2 inhibited growth and enhanced the cytotoxic effects of paclitaxel. Treatment of well established BT-474 breast cancer xenografts overexpressing HER2 in athymic mice with rhuMAb HER2 resulted in a dose-dependent antitumor activity. In combination studies, treatment with paclitaxel and rhuMAb HER2 or doxorubicin and rhuMAb HER2 resulted in greater inhibition of growth than that observed with any agent alone. The combination of paclitaxel and rhuMAb HER2 resulted in the highest tumor growth inhibition and had a significantly superior complete tumor regression rate when compared with either paclitaxel or rhuMAb HER2 alone. Clinical trials that are built on these results are under way.
1 Supported in part by an American Society of Clinical Oncology Career Development Award (to J. B.), NIH Grant CA65746, and Specialized Programs of Research Excellence Grant p50-CA58207 from The National Cancer Institute.
2 To whom requests for reprints should be addressed, at Medical Oncology Service, Vall d'Hebron University Hospital, Paseo Vall d'Hebrón 119–129, Barcelona 08035, Spain. Phone: 011-34-93-2746077; Fax: 011-34-93-2746059; E-mail: baselga@hg.vhebron.es.
3 Present address: U. T. M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030.
Received 2/ 9/98. Accepted 5/ 1/98.
This article has been cited by other articles:
|
|
 |
|
  V. Serra, B. Markman, M. Scaltriti, P. J.A. Eichhorn, V. Valero, M. Guzman, M. L. Botero, E. Llonch, F. Atzori, S. Di Cosimo, et al. NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations Cancer Res., October 1, 2008; 68(19): 8022 - 8030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Richmond and Y. Su Mouse xenograft models vs GEM models for human cancer therapeutics Dis. Model. Mech., September 1, 2008; 1(2-3): 78 - 82. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Rayson, D. Richel, S. Chia, C. Jackisch, S. van der Vegt, and T. Suter Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies Ann. Onc., September 1, 2008; 19(9): 1530 - 1539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Klechevsky, M. Gallegos, G. Denkberg, K. Palucka, J. Banchereau, C. Cohen, and Y. Reiter Antitumor Activity of Immunotoxins with T-Cell Receptor-like Specificity against Human Melanoma Xenografts Cancer Res., August 1, 2008; 68(15): 6360 - 6367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Belkhiri, A. A. Dar, D. F. Peng, M. H. Razvi, C. Rinehart, C. L. Arteaga, and W. El-Rifai Expression of t-DARPP Mediates Trastuzumab Resistance in Breast Cancer Cells Clin. Cancer Res., July 15, 2008; 14(14): 4564 - 4571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Piao, Y. Wang, Y. Adachi, H. Yamamoto, R. Li, A. Imsumran, H. Li, T. Maehata, M. Ii, Y. Arimura, et al. Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas Mol. Cancer Ther., June 1, 2008; 7(6): 1483 - 1493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H.E. Baker, K. E. Lindquist, L. A. Huxham, A. H. Kyle, J. T. Sy, and A. I. Minchinton Direct Visualization of Heterogeneous Extravascular Distribution of Trastuzumab in Human Epidermal Growth Factor Receptor Type 2 Overexpressing Xenografts Clin. Cancer Res., April 1, 2008; 14(7): 2171 - 2179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Park, M. Terabe, J. C. Steel, G. Forni, Y. Sakai, J. C. Morris, and J. A. Berzofsky Therapy of Advanced Established Murine Breast Cancer with a Recombinant Adenoviral ErbB-2/neu Vaccine Cancer Res., March 15, 2008; 68(6): 1979 - 1987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Azambuja, V. Durbecq, D. D. Rosa, M. Colozza, D. Larsimont, M. Piccart-Gebhart, and F. Cardoso HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer Ann. Onc., February 1, 2008; 19(2): 223 - 232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Emanuel, T. V. Hughes, M. Adams, C. A. Rugg, A. Fuentes-Pesquera, P. J. Connolly, N. Pandey, S. Moreno-Mazza, J. Butler, V. Borowski, et al. Cellular and in Vivo Activity of JNJ-28871063, A Nonquinazoline Pan-ErbB Kinase Inhibitor That Crosses the Blood-Brain Barrier and Displays Efficacy against Intracranial Tumors Mol. Pharmacol., February 1, 2008; 73(2): 338 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Catania, M. Medici, E. Magni, E. Munzone, D. Cardinale, L. Adamoli, G. Sanna, I. Minchella, D. Radice, A. Goldhirsch, et al. Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination Ann. Onc., December 1, 2007; 18(12): 1969 - 1975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Jani, R. S. Finn, M. Campbell, K. G. Coleman, R. D. Connell, N. Currier, E. O. Emerson, E. Floyd, S. Harriman, J. C. Kath, et al. Discovery and Pharmacologic Characterization of CP-724,714, a Selective ErbB2 Tyrosine Kinase Inhibitor Cancer Res., October 15, 2007; 67(20): 9887 - 9893. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Kumar, T. P. Quinn, and S. L. Deutscher Evaluation of an 111In-Radiolabeled Peptide as a Targeting and Imaging Agent for ErbB-2 Receptor Expressing Breast Carcinomas Clin. Cancer Res., October 15, 2007; 13(20): 6070 - 6079. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Stavenhagen, S. Gorlatov, N. Tuaillon, C. T. Rankin, H. Li, S. Burke, L. Huang, S. Johnson, E. Bonvini, and S. Koenig Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor Cells In vitro and Controls Tumor Expansion In vivo via Low-Affinity Activating Fc{gamma} Receptors Cancer Res., September 15, 2007; 67(18): 8882 - 8890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Taylor, D. Hershman, N. Shah, N. Suciu-Foca, D. P. Petrylak, R. Taub, L. Vahdat, B. Cheng, M. Pegram, K. L. Knutson, et al. Augmented HER-2 Specific Immunity during Treatment with Trastuzumab and Chemotherapy Clin. Cancer Res., September 1, 2007; 13(17): 5133 - 5143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H.A. Hussain, G. R. MacVicar, D. P. Petrylak, R. L. Dunn, U. Vaishampayan, P. N. Lara Jr, G. S. Chatta, D. M. Nanus, L. M. Glode, D. L. Trump, et al. Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/neu-Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial J. Clin. Oncol., June 1, 2007; 25(16): 2218 - 2224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Thurber, S. C. Zajic, and K. D. Wittrup Theoretic Criteria for Antibody Penetration into Solid Tumors and Micrometastases J. Nucl. Med., June 1, 2007; 48(6): 995 - 999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Koyama, Y. Hama, Y. Urano, D. M. Nguyen, P. L. Choyke, and H. Kobayashi Spectral Fluorescence Molecular Imaging of Lung Metastases Targeting HER2/neu Clin. Cancer Res., May 15, 2007; 13(10): 2936 - 2945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Rubinstein, M. Karmely, R. Ziv, I. Benhar, O. Leitner, S. Baron, B.-Z. Katz, and D. H. Wreschner MUC1/X Protein Immunization Enhances cDNA Immunization in Generating Anti-MUC1 {alpha}/{beta} Junction Antibodies that Target Malignant Cells Cancer Res., December 1, 2006; 66(23): 11247 - 11253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Pieretti-Vanmarcke, P. K. Donahoe, L. A. Pearsall, D. M. Dinulescu, D. C. Connolly, E. F. Halpern, M. V. Seiden, and D. T. MacLaughlin Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer PNAS, November 14, 2006; 103(46): 17426 - 17431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Abi-Habib, R. Singh, S. Liu, T. H. Bugge, S. H. Leppla, and A. E. Frankel A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types. Mol. Cancer Ther., October 1, 2006; 5(10): 2556 - 2562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kimura, T. Sawada, M. Komatsu, M. Inoue, K. Muguruma, T. Nishihara, Y. Yamashita, N. Yamada, M. Ohira, and K. Hirakawa Antitumor Effect of Trastuzumab for Pancreatic Cancer with High HER-2 Expression and Enhancement of Effect by Combined Therapy with Gemcitabine. Clin. Cancer Res., August 15, 2006; 12(16): 4925 - 4932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Menendez, I. Mehmi, and R. Lupu Trastuzumab in Combination With Heregulin-Activated Her-2 (erbB-2) Triggers a Receptor-Enhanced Chemosensitivity Effect in the Absence of Her-2 Overexpression J. Clin. Oncol., August 10, 2006; 24(23): 3735 - 3746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Vermeer, L. Panko, P. Karp, J. H. Lee, and J. Zabner Differentiation of human airway epithelia is dependent on erbB2 Am J Physiol Lung Cell Mol Physiol, August 1, 2006; 291(2): L175 - L180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Zhang, M. Zhang, K. Garmestani, V. S. Talanov, P. S. Plascjak, B. Beck, C. Goldman, M. W. Brechbiel, and T. A. Waldmann Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25 Blood, August 1, 2006; 108(3): 1007 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Testi and A. Cabras Dove in Flight: Who Will Save the Dove? International Journal of Surgical Pathology, April 1, 2006; 14(2): 144 - 144. [PDF]
|
|
|
|
|
|
P. Papaldo, A. Fabi, G. Ferretti, M. Mottolese, A. M. Cianciulli, B. Di Cocco, M. S. Pino, P. Carlini, S. Di Cosimo, I. Sacchi, et al. A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease Ann. Onc., April 1, 2006; 17(4): 630 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith, L. Gianni, J. Baselga, R. Bell, C. Jackisch, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med., October 20, 2005; 353(16): 1659 - 1672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bali, M. Pranpat, R. Swaby, W. Fiskus, H. Yamaguchi, M. Balasis, K. Rocha, H.-G. Wang, V. Richon, and K. Bhalla Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2 Clin. Cancer Res., September 1, 2005; 11(17): 6382 - 6389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Sartelet, E Lagonotte, M Lorenzato, I Duval, C Lechki, C Rigaud, J Cucherousset, A Durlach, O Graesslin, P Abboud, et al. Comparison of liquid based cytology and histology for the evaluation of HER-2 status using immunostaining and CISH in breast carcinoma J. Clin. Pathol., August 1, 2005; 58(8): 864 - 871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Terry, J. M. Lubieniecka, W. Kwan, S. Liu, and T. O. Nielsen Hsp90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Prevents Synovial Sarcoma Proliferation via Apoptosis in In vitro Models Clin. Cancer Res., August 1, 2005; 11(15): 5631 - 5638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Han, D. Kang, J. E. Lee, I. A. Park, J.-Y. Choi, K.-M. Lee, J. Y. Bae, S. Kim, E.-S. Shin, J. E. Lee, et al. A Haplotype Analysis of HER-2 Gene Polymorphisms: Association with Breast Cancer Risk, HER-2 Protein Expression in the Tumor, and Disease Recurrence in Korea Clin. Cancer Res., July 1, 2005; 11(13): 4775 - 4778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Bianco, T. Troiani, G. Tortora, and F. Ciardiello Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S159 - S171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Nemunaitis, I. Eiseman, C. Cunningham, N. Senzer, A. Williams, P. F. Lenehan, S. C. Olson, P. Bycott, M. Schlicht, R. Zentgraff, et al. Phase 1 Clinical and Pharmacokinetics Evaluation of Oral CI-1033 in Patients with Refractory Cancer Clin. Cancer Res., May 15, 2005; 11(10): 3846 - 3853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z-H Xian, S-H Zhang, W-M Cong, W-Q Wu, and M-C Wu Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma J. Clin. Pathol., May 1, 2005; 58(5): 500 - 503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Baselga and C. L. Arteaga Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer J. Clin. Oncol., April 10, 2005; 23(11): 2445 - 2459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Solit, Y. She, J. Lobo, M. G. Kris, H. I. Scher, N. Rosen, and F. M. Sirotnak Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to Paclitaxel Clin. Cancer Res., March 1, 2005; 11(5): 1983 - 1989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zhang, Z. Zhang, C. K. Goldman, J. Janik, and T. A. Waldmann Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody Blood, February 1, 2005; 105(3): 1231 - 1236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-F. Le, A. Lammayot, D. Gold, Y. Lu, W. Mao, T. Chang, A. Patel, G. B. Mills, and R. C. Bast Jr. Genes Affecting the Cell Cycle, Growth, Maintenance, and Drug Sensitivity Are Preferentially Regulated by Anti-HER2 Antibody through Phosphatidylinositol 3-Kinase-AKT Signaling J. Biol. Chem., January 21, 2005; 280(3): 2092 - 2104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zhang, Z. Zhang, K. Garmestani, C. K. Goldman, J. V. Ravetch, M. W. Brechbiel, J. A. Carrasquillo, and T. A. Waldmann Activating Fc Receptors Are Required for Antitumor Efficacy of the Antibodies Directed toward CD25 in a Murine Model of Adult T-Cell Leukemia Cancer Res., August 15, 2004; 64(16): 5825 - 5829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Dasmahapatra, P. Didolkar, M. C. Alley, S. Ghosh, E. A. Sausville, and K. K. Roy In vitro Combination Treatment with Perifosine and UCN-01 Demonstrates Synergism against Prostate (PC-3) and Lung (A549) Epithelial Adenocarcinoma Cell Lines Clin. Cancer Res., August 1, 2004; 10(15): 5242 - 5252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Menendez, L. Vellon, I. Mehmi, B. P. Oza, S. Ropero, R. Colomer, and R. Lupu Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells PNAS, July 20, 2004; 101(29): 10715 - 10720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Ballangrud, W.-H. Yang, S. Palm, R. Enmon, P. E. Borchardt, V. A. Pellegrini, M. R. McDevitt, D. A. Scheinberg, and G. Sgouros Alpha-Particle Emitting Atomic Generator (Actinium-225)-Labeled Trastuzumab (Herceptin) Targeting of Breast Cancer Spheroids: Efficacy versus HER2/neu Expression Clin. Cancer Res., July 1, 2004; 10(13): 4489 - 4497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Benoit, A. Chariot, L. Delacroix, V. Deregowski, N. Jacobs, M.-P. Merville, and V. Bours Caspase-8-Dependent HER-2 Cleavage in Response to Tumor Necrosis Factor {alpha} Stimulation Is Counteracted by Nuclear Factor {kappa}B through c-FLIP-L Expression Cancer Res., April 15, 2004; 64(8): 2684 - 2691. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Rojanala, H. Han, R. M. Munoz, W. Browne, R. Nagle, D. D. Von Hoff, and D. J. Bearss The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer Mol. Cancer Ther., April 1, 2004; 3(4): 451 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Warburton, W. H. Dragowska, K. Gelmon, S. Chia, H. Yan, D. Masin, T. Denyssevych, A. E. Wallis, and M. B. Bally Treatment of HER-2/neu Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/neu and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction Clin. Cancer Res., April 1, 2004; 10(7): 2512 - 2524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Mandler, H. Kobayashi, E. R. Hinson, M. W. Brechbiel, and T. A. Waldmann Herceptin-Geldanamycin Immunoconjugates: Pharmacokinetics, Biodistribution, and Enhanced Antitumor Activity Cancer Res., February 15, 2004; 64(4): 1460 - 1467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sapra, E. H. Moase, J. Ma, and T. M. Allen Improved Therapeutic Responses in a Xenograft Model of Human B Lymphoma (Namalwa) for Liposomal Vincristine versus Liposomal Doxorubicin Targeted via Anti-CD19 IgG2a or Fab' Fragments Clin. Cancer Res., February 1, 2004; 10(3): 1100 - 1111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Perez and R. Rodeheffer Clinical Cardiac Tolerability of Trastuzumab J. Clin. Oncol., January 15, 2004; 22(2): 322 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Herrmann, H.-A. Lehr, I. Drexler, G. Sutter, J. Hengstler, U. Wollscheid, and B. Seliger HER-2/neu-Mediated Regulation of Components of the MHC Class I Antigen-Processing Pathway Cancer Res., January 1, 2004; 64(1): 215 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Kirsch and F. H. Hochberg Targeting HER2 in Brain Metastases from Breast Cancer Clin. Cancer Res., November 15, 2003; 9(15): 5435 - 5436. [Full Text] [PDF]
|
|
|
|
|
|
P. M. Grossi, H. Ochiai, G. E. Archer, R. E. McLendon, M. R. Zalutsky, A. H. Friedman, H. S. Friedman, D. D. Bigner, and J. H. Sampson Efficacy of Intracerebral Microinfusion of Trastuzumab in an Athymic Rat Model of Intracerebral Metastatic Breast Cancer Clin. Cancer Res., November 15, 2003; 9(15): 5514 - 5520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Cuadrado, M. d. C. Moreno Koch, C. F. Perez, L. M. Castejon Castan, C. P. Villalobos, M. J. Gonzalez Mateos, and C. L. Olmos Immunomodulation in Established Murine Tumors: Response and Survival Rate Enhancement by Blood Leukocyte-Augmenting Substance 236 (Cl-), a Novel Synthetic Compound Clin. Cancer Res., November 15, 2003; 9(15): 5776 - 5785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Leyland-Jones, K. Gelmon, J.-P. Ayoub, A. Arnold, S. Verma, R. Dias, and P. Ghahramani Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel J. Clin. Oncol., November 1, 2003; 21(21): 3965 - 3971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Liang, Y. Lu, W. Jin, K. K. Ang, L. Milas, and Z. Fan Sensitization of breast cancer cells to radiation by trastuzumab Mol. Cancer Ther., November 1, 2003; 2(11): 1113 - 1120. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zhou, J. Chen, M. Mokotoff, R. Zhong, L. D. Shultz, and E. D. Ball Bombesin/Gastrin-Releasing Peptide Receptor: A Potential Target for Antibody-Mediated Therapy of Small Cell Lung Cancer Clin. Cancer Res., October 15, 2003; 9(13): 4953 - 4960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Fuino, P. Bali, S. Wittmann, S. Donapaty, F. Guo, H. Yamaguchi, H.-G. Wang, P. Atadja, and K. Bhalla Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B Mol. Cancer Ther., October 1, 2003; 2(10): 971 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Plum, A. D. Hanson, K. M. Volker, H. A. Vu, B. K. L. Sim, W. E. Fogler, and A. H. Fortier Synergistic Activity of Recombinant Human Endostatin in Combination with Adriamycin: Analysis of in Vitro Activity on Endothelial Cells and in Vivo Tumor Progression in an Orthotopic Murine Mammary Carcinoma Model Clin. Cancer Res., October 1, 2003; 9(12): 4619 - 4626. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Pellegrini, M. Falleni, A. Marchetti, B. Cassani, M. Miozzo, F. Buttitta, M. Roncalli, G. Coggi, and S. Bosari HER-2/Neu Alterations in Non-Small Cell Lung Cancer: A Comprehensive Evaluation by Real Time Reverse |
